Pre-Exposure 5 8 Prophylaxis (PrEP) by the Numbers $3 Efficacy, regulatory 7 1 approval and more
AUGUST 2016 %6 avac.org PrEP is the use of ARVs to reduce HIV risk in people who are HIV-negative. Daily oral PrEP, the one form of PrEP proven to work today, is recommended by the World Health Pre-Exposure Prophylaxis Organization as an additional option for all people at substantial risk of HIV. In spite of this endorsement and the need for new tools, different countries are moving at different speeds. Many are looking to demonstration projects—small-scale pilots (PrEP) by the Numbers that provide information on how to deliver oral PrEP in real-world settings. Advocates will look to countries to develop policies and plans to expand PrEP access. Now is the time to take regulatory action, learn from demonstration projects and fast-track E icacy regulatory status a more plans for scale-up. Other formulations of ARV-based prevention are also being evaluated and could provide additional options in the future.
PrEP or s i ou a e t E ective ess a here ce i rials o ral a opical e o ovir- ase Preve tio
100 P (te o ovir Trials of oral and topical gel - osi g) 80 tenofovir-based PrEP show E -PrEP that these strategies reduce 60 PE ( ) risk of HIV infection if they 40 iPrEx are used correctly and Part ers PrEP ( ) 20 consistently. Higher adherence Part ers PrEP ( ) is directly linked to greater ect iv e e ss ( ) 0 P ( ) levels of protection. E -20 E ( ) -40 Calculations based on E ( ) analyses involving a subset -60 E (te o ovir gel of total trial participants. 10 20 30 40 50 60 70 80 90 aily osi g) Perce tage o participa ts samples that ha etectable rug levels